A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Giessen, Clemens ^a   von Weikersthal, Ludwig F ^b   Hinke, Axel ^c   Stintzing, Sebastian ^a   Kullmann, Frank ^d   Vehling Kaiser, Ursula ^e   Mayerle, Julia ^f   Bangerter, Markus ^g   Denzlinger, Claudio ^h   Sieber, Markus ⁱ   Teschendorf, Christian ^j   Freiberg Richter, Jens ^k   Schulz, Christoph ^a   Modest, Dominik P ^a   Moosmann, Nicolas ^a   Aubele, Philipp ^a   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Gesundheitszentrum St Marien GmbH   (Germany)

^c WiSP GmbH   (Germany)

^d Klinikum Weiden   (Germany)

^e Oncological Practice   (Germany)

^f UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^g Oncological Practice Augsburg ^*  (Germany)

^h MARIENHOSPITAL STUTTGART   (Germany)

ⁱ Kreiskrankenhaus Gummersbach   (Germany)

^j St Josefs Hospital Dormund Hörde   (Germany)

^k Oncological Practice   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; MONOCLONAL ANTIBODY;

ARTICLE; BLOOD ANALYSIS; CANCER GROWTH; CANCER SURVIVAL; COLON RESECTION; COLORECTAL CANCER; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FUNCTIONAL STATUS; METASTASIS POTENTIAL; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TISSUE SECTION; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; MALE; METASTASIS; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; MALE; NEOPLASM METASTASIS; QUALITY OF LIFE;

EID: 80052029599     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-367     Document Type: Article

References (29)

1. Adam R, Haller DG, Poston G, Raoul J-L, Spano J-P, Tabernero J, Van Cutsem E. Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Annals of Oncology 2010,
2. Petrelli NJ, Abbruzzese J, Mansfield P, Minsky B. Hepatic resection: the last surgical frontier for colorectal cancer. J Clin Oncol 2005, 23(20):4475-7.
3. Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM, Sargent DJ. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol 2008, 26(2):183-9. 10.1200/JCO.2007.13.8099, 18182660.
4. Feliu J, Salut A, Safont M, Losa F, Garcia C, Bosch C, Escudero P, Lopez R, Bolanos M, Gonzalez-Baron M, . ONCOPAZ group First-line treatment with bevacizumab plus capecitabine for elderly patients with metastatic colorectal cancer: BECA trial. ASCO Meeting Abstracts 2008, 26(15_suppl):15120. ONCOPAZ group.
5. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010, 28(19):3191-8. 10.1200/JCO.2009.27.7723, 20516443.
6. Ducreux M, Adenis A, Mendiboure J, Francois E, Boucher E, Chauffert B, Ychou M, Pierga J, Montoto-Grillot C, Conroy T. Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study). ASCO Meeting Abstracts 2009, 27(15S):4086.
7. Reinacher-Schick AC, Kubicka S, Freier W, Arnold D, Dietrich G, Geissler M, Hegewisch-Becker S, Graeven U, Schmoll H, Schmiegel W. Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). ASCO Meeting Abstracts 2008, 26(15_suppl):4030.
8. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007, 25(30):4779-86. 10.1200/JCO.2007.11.3357, 17947725.
9. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GJ, Tesselaar ME, Slee PH, Werter MJ, Mol L, Dalesio O, Punt CJ. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007, 370(9582):135-42. 10.1016/S0140-6736(07)61086-1, 17630036.
10. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001, 19(18):3801-7.
11. Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermuller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V. Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104--A Randomized Trial of the German AIO CRC Study Group. J Clin Oncol 2011,
12. Schmiegel W, Pox C, Reinacher-Schick A, Adler G, Arnold D, Fleig W, Folsch UR, Fruhmorgen P, Graeven U, Heinemann V, Hohenberger W, Holstege A, Junginger T, Kopp I, Kuhlbacher T, Porschen R, Propping P, Riemann JF, Rodel C, Sauer R, Sauerbruch T, Schmitt W, Schmoll HJ, Seufferlein T, Zeitz M, Selbmann HK. S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol 2010, 48(1):65-136. 10.1055/s-0028-1109936, 20072998.
13. Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R, Riemann J, Rodel C, Sauer R, Wieser M, Schmitt W, Schmoll HJ, Seufferlein T, Kopp I, Pox C. [Update S3-guideline "colorectal cancer" 2008]. Z Gastroenterol 2008, 46(8):799-840. 10.1055/s-2008-1027726, 18759205.
14. Peto R, Peto J. Asymptotically Efficient Rank Invariant Test Procedures. Journal of the Royal Statistical Society. Series A (General) 1972, 135(2):185-207.
15. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977, 35(1):1-39. 10.1038/bjc.1977.1, 2025310, 831755.
16. Prentice RL. Linear rank tests with right censored data. Biometrika 1978, 65(1):167-179.
17. Lan G, Demets D. Discrete sequential boundaries for clinical trials. Biometrika 1983, 70(3):659-663.
18. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979, 35(3):549-56. 10.2307/2530245, 497341.
19. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998, 34(8):1274-81. 10.1016/S0959-8049(98)00058-6, 9849491.
20. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001, 40(2):85-104. 10.2165/00003088-200140020-00002, 11286326.
21. Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev 2008, 34(7):656-69. 10.1016/j.ctrv.2008.05.002, 18558463.
22. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3(5):391-400. 10.1038/nrd1381, 15136787.
23. Shibuya M. Angiogenesis regulated by VEGF and its receptors and its clinical application. Rinsho Ketsueki 2009, 50(5):404-12.
24. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007, 370(9582):143-52. 10.1016/S0140-6736(07)61087-3, 17630037.
25. Bouche O, Castaing M, Etienne PL, Texereau P, Auby D, Bedenne L, Rougier P, Gargot D, Gasmi M, Ducreux M. Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): Preliminary results. ASCO Meeting Abstracts 2007, 25(18_suppl):4069.
26. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009, 27(22):3677-83. 10.1200/JCO.2008.20.5278, 2720081, 19470929.
27. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26(12):2013-9. 10.1200/JCO.2007.14.9930, 18421054.
28. de Gramont A, Buyse M, Abrahantes JC, Burzykowski T, Quinaux E, Cervantes A, Figer A, Lledo G, Flesch M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, Andre T, Tabah-Fisch I, Tournigand C. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J Clin Oncol 2007, 25(22):3224-9. 10.1200/JCO.2006.10.4380, 17664470.
29. Allegra C, Blanke C, Buyse M, Goldberg R, Grothey A, Meropol NJ, Saltz L, Venook A, Yothers G, Sargent D. End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol 2007, 25(24):3572-5. 10.1200/JCO.2007.12.1368, 17704403.